Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy
Kizer JR, Madias C, Wilner B, Vaughan CJ, Mushlin AI, Trushin P, Gotto AM, Pasternak RC
The American journal of cardiology · 37 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Heart, Lung, and Blood Institute
- Gobierno
- NHLBI NIH HHS
- Subvenciones
- National Heart, Lung, and Blood Institute (K23-HL070854)
Según 2 financiadores declarados.
Publicación
- Publicado
- 2010-03-22 · Am J Cardiol · vol. 105 · número 9 · págs. 1289–1296
- Editorial
- Elsevier BV
- Citado
- 52 citas · más que el 98% de estudios similares · 9.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 40 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Cancer, Lipids, and Metabolism · Cholesterol and Lipid Metabolism
- Palabras clave
- statins, LDL cholesterol, coronary artery disease, all-cause mortality, lipid-lowering therapy, cardiovascular risk reduction, trial design, meta-regression
- MeSH
- humans, death, sudden, cardiac, hydroxymethylglutaryl-coa reductase inhibitors, prognosis, risk factors, regression analysis, united states, cholesterol, ldl, coronary artery disease, randomized controlled trials as topic
8 autores
- Jorge R. Kizer🇺🇸 · autor de correspondenciaWeill Cornell Medicine
- Christopher A. Madias🇺🇸Tufts Medical Center
- Brian F. Wilner
- Carl J. Vaughan🇮🇪Mercy University Hospital
- Alvin I. Mushlin🇺🇸Weill Cornell Medicine
- Paula Trushin🇺🇸Weill Cornell Medicine
- Antonio M. Gotto🇺🇸Weill Cornell Medicine
- Richard C. Pasternak🇺🇸Merck & Co., Inc., Rahway, NJ, USA (United States)
Resumen
El texto original del estudio, en el idioma en que se publicó.
Multiple randomized controlled trials (RCTs) have established the efficacy of statins for the prevention of cardiovascular disease. The benefits observed are often framed in terms of percentage reductions in low-density lipoprotein (LDL) cholesterol from baseline or percentage reductions between control and treatment groups, although epidemiologic data suggest that the absolute intergroup difference in LDL cholesterol (DeltaLDL(Control-Rx)) is the more informative measure. A systematic review of large-scale trials of statins versus placebo, usual care, or active (lower dose statin) control was conducted to calculate updated summary estimates of risk reduction in coronary artery disease and all-cause mortality. Meta-regression analysis was used to ascertain the relations of different LDL cholesterol metrics to outcomes. In 20 eligible RCTs, there were significant overall reductions for coronary artery disease (odds ratio 0.72, 95% confidence interval 0.67 to 0.78) and mortality (odds ratio 0.89, 95% confidence interval 0.84 to 0.94), but with substantial variability in trial results. DeltaLDL(Control-Rx) was the strongest determinant of coronary artery disease risk reduction, particularly after excluding active-comparator studies, and was independent of baseline LDL cholesterol. In contrast, baseline LDL cholesterol edged out DeltaLDL(Control-Rx) as the strongest determinant of mortality, but neither was significant after the exclusion of active-comparator studies. The exclusion of 3 RCTs involving distinct populations, however, rendered DeltaLDL(Control-Rx) the predominant determinant of mortality reduction. In conclusion, these findings underscore the primacy of absolute reductions in LDL cholesterol in the design and interpretation of RCTs of lipid-lowering therapies and in framing treatment recommendations on the basis of the proved coronary benefits of these drugs.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.